How Low Does Merck Need To Go? FDA Safety Concerns May Cut Suvorexant’s Dosing
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will ask an advisory committee whether Merck’s insomnia drug should employ the tiered dosing schedule proposed for the elderly and non-responders, but the agency seems inclined towards a dose even lower that the ones that were used in Phase III.